You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. T7 RNA polymerase engineering and RNA amplification

    SBC: Accacia International LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Expanding use of microarray systems for global gene expression profiling is leading biological research, providing diagnostic and prognostic value to physicians and facilitating target discovery during drug and vaccine development. There is strong interest in extending this microarray capability to more RNA-limited material to the point that a single cell can b ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  2. N/A

    SBC: ACCESS PHARMACEUTICALS, INC.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  3. VALIDATION OF FLUORESCENT DEOXYGLUCOSE (2-NBDG) IN TUMORS

    SBC: 3GEN, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): A new fluorescent analogue of d-glucose, 2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-2- deoxyglucose (2-NBDG), was recently developed, but has not been characterized as a marker of glucose uptake in cancer cells. Validating this new tracer as a glucose analogue for optical imaging of superficial tumors may have a major impact on clinical and preclinical imag ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Therapy for gastrointestinal disorders

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The overall goal of this research proposal is to determine the effectiveness of recombinant human lactoferrin (rhLF) for treating gastrointestinal (GI) disorders. This Phase II proposal will focus on the ability of rhLF to treat the 01 side effects of non-steroidal anti-inflammatory drugs (NSAIDs), a class of drugs widely-us ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  5. Therapy for gastrointestinal disorders

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The overall goal of this research proposal is to determine the effectiveness of recombinant human lactoferrin (rhLF) for treating gastrointestinal (GI) disorders. This Phase II proposal will focus on the ability of rhLF to treat the 01 side effects of non-steroidal anti-inflammatory drugs (NSAIDs), a class of drugs widely-us ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  6. Recombinant Lactoferrin and Necrotizing Enterocolitis

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This feasibility study is based on our hypothesis that recombinant human lactoferrin [rhLF] can prevent or reduce severity of necrotizing enterocolitis [NEC]. NEC is mainly a disease of very low birth weight [VLBW] human infants. It is a leading cause of morbidity and mortality in neonatal intensive care units, with incidence of approximately 10 percent in VLBW ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a humanized anti-CD47 antibody for treatment of tissue ischemia.

    SBC: VASCULOX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Nitric oxide (NO) is a critical regulator of cardiovascular physiology, coordinating the activities of the endothelium, the vessel wall and circulating cells to optimize the flow of blood and oxygen to tissues. Increasing the bioavailability of NO should provide therapeutic benefit in the treatment of many diseases ascribed to insufficient NO bioavailability. A ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. T7 RNA polymerase engineering and RNA amplification

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Microarrays are powerful tools that can impact new diagnostic procedures and expedite the drug development process. A significant but largely unrealized application is gene expression analysis from RNAlimited samples, such as blood, needle biopsies, laser capture microdissection (LCM) samples, and even single cells. The most widely used T7 RNA polymerase-based ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  9. Single molecule fluorescence detection of fragile X mutations

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Fragile X Syndrome (FXS), is the most common form of inherited mental retardation, affecting 1 in 4000 males and about 1 in 6000 females of all ethnicities. Additionally, carrier frequencies are quite high. About 1 in 250 females carry Fragile X and about 1 in 800 men carry Fragile X. FXS was one of the first human diseases to be linked to an expansion of trip ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Molecular tools for Bunyavirus antiviral screening

    SBC: APATH, LLC            Topic: N/A

    DESCRIPTION (provided by investigator): Several viruses in the family Bunyaviridae are significant human pathogens and potential agents of bioterrorism. Vaccines against some of these viruses do exist, but with the exception of ribavarin, there are no broad-spectrum antiviral compounds capable of inhibiting replication of more than one member of the family. Using LaCrosse virus (LAC) as a prototyp ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government